Greenleaf Trust grew its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 56,948.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,249 shares of the medical research company’s stock after buying an additional 22,210 shares during the quarter. Greenleaf Trust’s holdings in Laboratory Corp. of America were worth $3,549,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LH. Zions Bancorporation grew its stake in Laboratory Corp. of America by 7,444.4% in the third quarter. Zions Bancorporation now owns 679 shares of the medical research company’s stock worth $103,000 after purchasing an additional 670 shares in the last quarter. Hourglass Capital LLC bought a new position in Laboratory Corp. of America in the fourth quarter worth approximately $207,000. Teacher Retirement System of Texas bought a new position in Laboratory Corp. of America in the third quarter worth approximately $210,000. Calton & Associates Inc. bought a new position in Laboratory Corp. of America in the fourth quarter worth approximately $213,000. Finally, Flagship Harbor Advisors LLC bought a new position in Laboratory Corp. of America in the fourth quarter worth approximately $224,000. 91.70% of the stock is currently owned by hedge funds and other institutional investors.

In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total transaction of $213,813.27. Following the sale, the director now owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by company insiders.

Shares of Laboratory Corp. of America Holdings (NYSE LH) opened at $171.01 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $17,152.28, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.48 and a beta of 0.93. Laboratory Corp. of America Holdings has a 52-week low of $134.10 and a 52-week high of $181.71.

Laboratory Corp. of America (NYSE:LH) last announced its earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.07. The business had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 billion. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.15 EPS. equities research analysts forecast that Laboratory Corp. of America Holdings will post 11.53 earnings per share for the current fiscal year.

Several research analysts recently issued reports on the company. Zacks Investment Research raised Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a research note on Friday, February 9th. Citigroup increased their price objective on Laboratory Corp. of America from $161.00 to $184.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Robert W. Baird set a $183.00 price objective on Laboratory Corp. of America and gave the stock a “hold” rating in a research note on Thursday, February 8th. Craig Hallum reissued a “buy” rating and issued a $204.00 price objective (up previously from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday, February 7th. Finally, ValuEngine raised Laboratory Corp. of America from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Laboratory Corp. of America presently has an average rating of “Buy” and an average target price of $180.73.

TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/02/14/greenleaf-trust-has-3-55-million-stake-in-laboratory-corp-of-america-holdings-lh.html.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.